Distinguishing substance-induced psychotic disorders (SIPD) from primary psychotic disorders with concurrent substance use remains a critical diagnostic challenge for treatment planning and prognostic counseling.
Objective:
To systematically review the clinical phenomenology of SIPD, identify distinguishing symptom patterns, and examine relationships between phenomenology and outcomes.
Methods:
A systematic search of PubMed, PsycINFO, and Web of Science (1990–2025) was conducted for studies examining clinical characteristics of SIPD using standardized diagnostic criteria and validated instruments. Study quality was assessed using the Newcastle-Ottawa Scale. The review was registered on PROSPERO (CRD42025123563; 19/11/2025).
Results:
Thirty-six studies encompassing over 80,000 individuals were included. Cannabis-induced psychosis was consistently characterized by prominent positive symptoms, preserved negative domains, and elevated affective and anxiety features, with transition rates to schizophrenia spectrum disorders ranging from 36% to 46%. Methamphetamine-induced psychosis presented along a phenomenological gradient, from simple persecutory delusions and tactile hallucinations in transient cases—accompanied by markedly elevated violence rates (75.6%)—to complex multimodal sensory disturbances in persistent presentations. Despite these substance-specific signatures, substantial phenomenological overlap with primary psychotic disorders and poor diagnostic stability, with 25% to 39% of initial SIPD diagnoses converting to primary disorders over follow-up, limit the utility of cross-sectional assessment alone. Superior antipsychotic response at lower doses emerged as a potential marker favoring substance-induced over primary etiology.
Conclusions:
SIPD exhibit distinctive phenomenological signatures varying by substance class, yet considerable overlap with primary psychotic disorders and poor diagnostic stability underscore the necessity of longitudinal monitoring and integrated psychiatric-addiction care.
AggarwalM.BanerjeeA.SinghS. M.MattooS. K.BasuD. (2012). Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications. Asian Journal of Psychiatry, 5(3), 220–224. https://doi.org/10.1016/j.ajp.2011.11.008
2.
AhmadkhanihaH.AyaziN.AlaviK.NajjarzadehganM.HadiF. (2022). The comparison between positive and negative symptoms severity in prolonged methamphetamine-induced psychotic disorder and schizophrenia. Basic and Clinical Neuroscience, 13(3), 325–333. https://doi.org/10.32598/bcn.2021.2837.1
AndreasenN. C. (1983). Scale for the assessment of negative symptoms (SANS). University of Iowa.
5.
AndreasenN. C. (1984). Scale for the assessment of positive symptoms (SAPS). University of Iowa.
6.
ArendtM.MortensenP. B.RosenbergR.PedersenC. B.WaltoftB. L. (2008). Familial predisposition for psychiatric disorder: Comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Archives of General Psychiatry, 65(11), 1269–1274. https://doi.org/10.1001/archpsyc.65.11.1269
7.
ArendtM.RosenbergR.FjordbackL.BrandholdtJ.FoldagerL.SherL.Munk-JørgensenP. (2008). Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. Psychological Medicine, 38(7), 935–945. https://doi.org/10.1017/S0033291707002450
8.
ArendtM.RosenbergR.FoldagerL.PertoG.Munk-JørgensenP. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. British Journal of Psychiatry, 187(6), 510–515. https://doi.org/10.1192/bjp.187.6.510
9.
ArgoteM.SescousseG.BrunelinJ.BaudinG.SchaubM. P.RabinR.SchnellT.RingenP. A.AndreassenO. A.AddingtonJ. M.BrambillaP.DelvecchioG.BechdolfA.WobrockT.Schneider-AxmannT.HerzigD.MohrC.Vila-BadiaR.RodieJ. U.. . . RollandB. (2023). Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: An individual participant data meta-analysis on 3053 individuals. EClinicalMedicine, 64, 102199. https://doi.org/10.1016/j.eclinm.2023.102199
10.
BaezaI.GraellM.MorenoD.Castro-FornielesJ.ParelladaM.González-PintoA.PayáB.SoutulloC.de la SernaE.ArangoC. (2009). Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research, 113(2–3), 129–137. https://doi.org/10.1016/j.schres.2009.04.005
11.
BrostedtE. M.MsghinaM.PerssonM.WettermarkB. (2017). Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: A cross-sectional study. BMC Psychiatry, 17(1), 416. https://doi.org/10.1186/s12888-017-1582-x
CatonC. L.DrakeR. E.HasinD. S.DominguezB.ShroutP. E.SametS.SchanzerB. (2005). Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry, 62(2), 137–145. https://doi.org/10.1001/archpsyc.62.2.137
14.
ChenC. K.LinS. K.ShamP. C.BallD.LohE. W.HsiaoC. C.ChiangY. L.ReeS. C.LeeC. H.MurrayR. M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine, 33(8), 1407–1414. https://doi.org/10.1017/s0033291703008353
15.
DavisJ.EyreH.JackaF. N.DoddS.DeanO.McEwenS.DebnathM.McGrathJ.MaesM.AmmingerP.McGorryP. D.PantelisC.BerkM. (2016). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience and Biobehavioral Reviews, 65, 185–194. https://doi.org/10.1016/j.neubiorev.2016.03.017
16.
DerogatisL. R. (1994). SCL-90-R: Administration, scoring and procedures manual. NCS Pearson.
17.
Di FortiM.MarconiA.CarraE.FraiettaS.TrottaA.BonomoM.BianconiF.Gardner-SoodP.O’ConnorJ.RussoM.StiloS. A.MarquesT. R.MondelliV.DazzanP.ParianteC.DavidA. S.GaughranF.AtakanZ.IyegbeC.. . . MurrayR. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry, 2(3), 233–238. https://doi.org/10.1016/S2215-0366(14)00117-5
18.
Di FortiM.QuattroneD.FreemanT. P.TripoliG.Gayer-AndersonC.QuigleyH.RodriguezV.JongsmaH. E.FerraroL.La CasciaC.La BarberaD.TarriconeI.BerardiD.SzökeA.ArangoC.TortelliA.VelthorstE.BernardoM.Del-BenC. M.. . . MurrayR. M. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6(5), 427–436. https://doi.org/10.1016/S2215-0366(19)30048-3
19.
DrakeR. E.CatonC. L.XieH.HsuE.GorroochurnP.SametS.HasinD. S. (2011). A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. American Journal of Psychiatry, 168(7), 742–748. https://doi.org/10.1176/appi.ajp.2011.10071051
20.
EdinoffA. N.SilverblattN. S.VervaekeH. E.HortonC. C.GirmaE.KayeA. D.KayeA.KayeJ. S.GarciaA. J.NeuchatE. E.EubanksT. N.VarrassiG.ViswanathO.UritsI. (2021). Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications. Psychopharmacology Bulletin, 51(2), 131–148. https://doi.org/10.64719/pb.4396
21.
FarniaV.ShakeriJ.TatariF.JuibariT. A.YazdchiK.BajoghliH.BrandS.AbdoliN.AghaeiA. (2014). Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. American Journal of Drug and Alcohol Abuse, 40(1), 10–15. https://doi.org/10.3109/00952990.2013.861843
22.
FasihpourB.MolaviS.ShariatS. V. (2013). Clinical features of inpatients with methamphetamine-induced psychosis. Journal of Mental Health, 22(4), 341–349. https://doi.org/10.3109/09638237.2012.745184
23.
FirstM. B. (1996). Structured clinical interview for DSM-IV Axis I disorders (SCID-I). Biometrics Research.
24.
GicasK. M.ChengA.PanenkaW. J.KimD. D.YauJ. C.ProcyshynR. M.StubbsJ. L.JonesA. A.BainsS.ThorntonA. E.LangD. J.VertinskyA. T.RauscherA.HonerW. G.BarrA. M. (2021). Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 106, 110084. https://doi.org/10.1016/j.pnpbp.2020.110084
25.
HajebiA.AminiH.KashaniL.SharifiV. (2018). Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. Early Intervention in Psychiatry, 12(5), 928–934. https://doi.org/10.1111/eip.12404
26.
HasinD. S.TrautmanK. D.MieleG. M.SametS.SmithM.EndicottJ. (1996). Psychiatric Research Interview for Substance and Mental Disorders (PRISM): Reliability for substance abusers. American Journal of Psychiatry, 153(9), 1195–1201.
27.
HidesL.DaweS.YoungR. M.KavanaghD. J. (2020). The reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in psychosis. Addiction, 102(1), 35–40.
28.
KayS. R.FiszbeinA.OplerL. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261
29.
KendlerK. S.OhlssonH.SundquistJ.SundquistK. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. American Journal of Psychiatry, 176(9), 711–719. https://doi.org/10.1176/appi.ajp.2019.18101217
30.
KittirattanapaiboonP.MahatnirunkulS.BooncharoenH.ThummawomgP.DumrongchaiU.ChuthaW. (2010). Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review, 29(4), 456–461. https://doi.org/10.1111/j.1465-3362.2010.00196.x
31.
KoskinenJ.LöhönenJ.KoponenH.IsohanniM.MiettunenJ. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia bulletin, 36(6), 1115–1130. https://doi.org/10.1093/schbul/sbp031
32.
MarshallM.LewisS.LockwoodA.DrakeR.JonesP.CroudaceT. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry, 62(9), 975–983. https://doi.org/10.1001/archpsyc.62.9.975
MathiasS.LubmanD. I.HidesL. (2008). Substance-induced psychosis: A diagnostic conundrum. Journal of Clinical Psychiatry, 69(3), 358–367. https://doi.org/10.4088/jcp.v69n0304
35.
McKetinR.BakerA. L.DaweS.VoceA.LubmanD. I. (2017). Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Research, 251, 349–354. https://doi.org/10.1016/j.psychres.2017.02.028
36.
McKetinR.GardnerJ.BakerA. L.DaweS.AliR.VoceA.LeachL. S.LubmanD. I. (2016). Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Research, 238, 166–171. https://doi.org/10.1016/j.psychres.2016.02.038
37.
McKetinR.LubmanD. I.BakerA. L.DaweS.AliR. L. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry, 70(3), 319–324. https://doi.org/10.1001/jamapsychiatry.2013.283
38.
MurrieB.LappinJ.LargeM.SaraG. (2020). Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 46(3), 505–516. https://doi.org/10.1093/schbul/sbz102
39.
Niemi-PynttäriJ. A.SundR.PutkonenH.VormaH.WahlbeckK.PirkolaS. P. (2013). Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 Finnish inpatient cases. Journal of Clinical Psychiatry, 74(01), e94–e99. https://doi.org/10.4088/jcp.12m07822
40.
O'ConnellJ.SunwooM.McGorryP.O’DonoghueB. (2019). Characteristics and outcomes of young people with substance induced psychotic disorder. Schizophrenia Research, 206, 257–262. https://doi.org/10.1016/j.schres.2018.11.007
PageM. J.McKenzieJ. E.BossuytP. M.BoutronI.HoffmannT. C.MulrowC. D.ShamseerL.TetzlaffJ. M.AklE. A.BrennanS. E.ChouR.GlanvilleJ.GrimshawJ. M.HróbjartssonA.LaluM. M.LiT.LoderE. W.Mayo-WilsonE.McDonaldS.. . MoherD. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
43.
PettersenH.LandheimA.SkeieI.BiongS.BrodahlM.OuteJ.DavidsonL. (2019). How social relationships influence substance use disorder recovery: A collaborative narrative study. Substance Abuse Research and Treatment, 13, 1178221819833379. https://doi.org/10.1177/1178221819833379
44.
PopayJ.RobertsH.SowdenA.PetticrewM.AraiL.RodgersM.BrittenN.RoenK.DuffyS. (2006). Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC Methods Programme Version 1, b92. Lancaster University.
45.
QuattroneD.FerraroL.TripoliG.La CasciaC.QuigleyH.QuattroneA.JongsmaH. E.Del PeschioS.GattoG.Gayer-AndersonC.JonesP. B.KirkbrideJ. B.La BarberaD.TarriconeI.BerardiD.TosatoS.LasalviaA.RichardsA.ArangoC.. . . Di FortiM. (2021). Daily use of high-potency cannabis is associated with more negative symptoms in first-episode psychosis patients: The EU-GEI case-control study. Psychological Medicine, 51(8), 1329–1337. https://doi.org/10.1017/S0033291720000082
46.
RicciV.CeciF.Di CarloF.Di MuzioI.CiavoniL.SantangeloM.Di SalvoG.PettorrusoM.MartinottiG.MainaG. (2023). First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness. Psychiatry Research, 320, 115053. https://doi.org/10.1016/j.psychres.2023.115053
47.
RicciV.ChiappiniS.MartinottiG.MainaG. (2025). Cannabis use and psychotic-like experiences: A systematic review of biological vulnerability, potency effects, and clinical trajectories. Psychiatry Research, 348, 116496. https://doi.org/10.1016/j.psychres.2025.116496
48.
RicciV.De BerardisD.MartinottiG.MainaG. (2024). New insight in psychotic cannabis withdrawal: Case series and brief overview. Rivista di Psichiatria, 59(6), 316–321. https://doi.org/10.1708/4386.43840
49.
RicciV.MainaG.MartinottiG. (2024). The loss of spatiality and temporality in twilight consciousness: The emergence of exogenous psychosis induced by novel psychoactive substances. Psychopathology, 57(3), 248–258. https://doi.org/10.1159/000536076
50.
RobinsL. N.WingJ.WittchenH. U.HelzerJ. E.BaborT. F.BurkeJ.FarmerA.JablenskiA.PickensR.RegierD. A. (1988). The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Archives of General Psychiatry, 45(12), 1069–1077.
51.
RognliE. B.HåkanssonA.BergeJ.BramnessJ. G. (2014). Does the pattern of amphetamine use prior to incarceration predict later psychosis? A longitudinal study of amphetamine users in the Swedish criminal justice system. Drug and Alcohol Dependence, 143, 219–224. https://doi.org/10.1016/j.drugalcdep.2014.07.037
52.
RognliE. B.HeibergI. H.JacobsenB. K.HøyeA.BramnessJ. G. (2023). Transition from substance-induced psychosis to schizophrenia spectrum disorder or bipolar disorder. American Journal of Psychiatry, 180(6), 437–444. https://doi.org/10.1176/appi.ajp.22010076
53.
RubioG.Marín-LozanoJ.FerreF.Martínez-GrasI.Rodriguez-JimenezR.SanzJ.Jimenez-ArrieroM. A.CarrascoJ. L.LoraD.JuradoR.López-TrabadaJ. R.PalomoT. (2012). Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. Comprehensive Psychiatry, 53(8), 1063–1070. https://doi.org/10.1016/j.comppsych.2012.04.013
54.
SchoelerT.PetrosN.Di FortiM.KlamerusE.FogliaE.AjnakinaO.Gayer-AndersonC.ColizziM.QuattroneD.BehlkeI.ShettyS.McGuireP.DavidA. S.MurrayR.BhattacharyyaS. (2016a). Association between continued cannabis use and risk of relapse in first-episode psychosis: A quasi-experimental investigation within an observational study. JAMA Psychiatry, 73(11), 1173–1179. https://doi.org/10.1001/jamapsychiatry.2016.2427
55.
SchoelerT.PetrosN.Di FortiM.KlamerusE.FogliaE.AjnakinaO.Gayer-AndersonC.ColizziM.QuattroneD.BehlkeI.ShettyS.McGuireP.DavidA. S.MurrayR.BhattacharyyaS. (2016b). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. Lancet Psychiatry, 3(10), 947–953. https://doi.org/10.1016/S2215-0366(16)30188-2
56.
SchoelerT.PetrosN.Di FortiM.KlamerusE.FogliaE.MurrayR.BhattacharyyaS. (2017). Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: A prospective analysis. Lancet Psychiatry, 4(8), 627–633. https://doi.org/10.1016/S2215-0366(17)30233-X
57.
SeddighR.Keshavarz-AkhlaghiA. A.ShariatiB. (2014). Treating methamphetamine-induced resistant psychosis with clozapine. Case Reports in Psychiatry, 2014, 845145. https://doi.org/10.1155/2014/845145
58.
SekiguchiY.OkadaT.OkumuraY. (2021). Treatment response distinguishes persistent type of methamphetamine psychosis from schizophrenia spectrum disorder among inmates at Japanese medical prison. Frontiers in Psychiatry, 12, 629315. https://doi.org/10.3389/fpsyt.2021.629315
59.
ShahD.ChandP.BandawarM.BenegalV.MurthyP. (2017). Cannabis induced psychosis and subsequent psychiatric disorders. Asian Journal of Psychiatry, 30, 180–184. https://doi.org/10.1016/j.ajp.2017.10.003
60.
StarzerM. S. K.NordentoftM.HjorthøjC. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry, 175(4), 343–350. https://doi.org/10.1176/appi.ajp.2017.17020223
61.
StrassmanR. J.QuallsC. R.UhlenhuthE. H.KellnerR. (1994). Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry, 51(2), 98–108. https://doi.org/10.1001/archpsyc.1994.03950020022002
62.
SulaimanA. H.GillJ. S.SaidM. A.ZainalN. Z.HusseinH. M.GuanN. C. (2013). A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. International Journal of Psychiatry in Clinical Practice, 17(2), 131–138. https://doi.org/10.3109/13651501.2012.667116
63.
TosatoS.LasalviaA.BonettoC.MazzonciniR.CristofaloD.De SantiK.BertaniM.BissoliS.LazzarottoL.MarrellaG.LamonacaD.RioloR.GardellinF.UrbaniA.TansellaM.RuggeriM. (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients: Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research, 47(4), 438–444. https://doi.org/10.1016/j.jpsychires.2012.11.009
64.
United Nations Office on Drugs and Crime. (2023). World Drug Report 2023. United Nations Publication.
65.
VolkowN. D.BlancoC. (2023). Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry, 22(2), 203–229. https://doi.org/10.1002/wps.21073
66.
WellsG. A.SheaB.O'ConnellD.PetersonJ.WelchV.LososM.TugwellP. (2000). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
67.
WilsonL.SzigetiA.KearneyA.ClarkeM. (2018). Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review. Schizophrenia Research, 197, 78–86. https://doi.org/10.1016/j.schres.2017.11.001
68.
ZarrabiH.KhalkhaliM.HamidiA.AhmadiR.ZavarmousaviM. (2016). Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. BMC Psychiatry, 16, 44. https://doi.org/10.1186/s12888-016-0745-5
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
